Behavioral
Bryan Medical Center
Bryan Medical Center was paid $57.10M by Medicaid between Jan 2018 and Dec 2024, across 430 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoBRYAN MEDICAL CENTER
LINCOLN, NE 68506
LINCOLN, NE 68506
33aNPI1528006103assigned 06/03/2006
33bProvider typeCounseling Psychologist
28Total paid$57.10M
24GClaims1,662,725
24DCodes billed430
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 170,479 | $5.88M | |
| 2019 | 198,621 | $6.83M | |
| 2020 | 214,221 | $6.87M | |
| 2021 | 380,804 | $12.23M | |
| 2022 | 396,863 | $12.78M | |
| 2023 | 207,407 | $8.00M | |
| 2024incomplete | 94,330 | $4.49M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 79,697 | 71,276 | $9.43M |
| 96361 | Intravenous infusion, hydration; each additional hour | 14% | 23,218 | 18,318 | $7.99M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 58,479 | 54,532 | $7.84M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 6,614 | 6,242 | $2.59M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 8,843 | 8,243 | $2.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 18,177 | 16,130 | $1.96M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.8% | 4,432 | 4,325 | $1.60M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 4,242 | 4,022 | $1.37M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.7% | 3,280 | 3,097 | $944K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 5,085 | 4,668 | $862K |
| G0378 | Hospital observation service, per hour | 1.5% | 16,484 | 7,361 | $854K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 7,882 | 7,533 | $812K |
418 more codes
| 59025 | Fetal non-stress test | 1.4% | 4,801 | $804K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 11,986 | $757K |
| H0018 | Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem | 1.2% | 3,270 | $676K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 14,257 | $675K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,762 | $529K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,139 | $473K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,585 | $417K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,195 | $397K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,030 | $386K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,200 | $381K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,239 | $355K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,020 | $353K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,130 | $341K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,793 | $329K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,505 | $321K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 534 | $303K |
| 95806 | <1% | 430 | $286K | |
| 93017 | <1% | 1,507 | $286K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 4,960 | $274K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,052 | $247K |
| 93971 | <1% | 1,728 | $228K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,344 | $215K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 31,570 | $212K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,756 | $210K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,432 | $209K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 282 | $207K |
| 12001 | <1% | 1,056 | $204K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,573 | $185K |
| 93458 | <1% | 123 | $183K | |
| 95811 | <1% | 349 | $181K | |
| 12011 | <1% | 875 | $179K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 259 | $171K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,243 | $165K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,634 | $159K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,164 | $158K |
| 97803 | <1% | 3,046 | $157K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 77,136 | $156K |
| 36415 | Collection of venous blood by venipuncture | <1% | 111,822 | $152K |
| 93976 | <1% | 805 | $150K | |
| 90870 | <1% | 1,095 | $145K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,347 | $134K |
| 80053 | Comprehensive metabolic panel | <1% | 39,545 | $131K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,473 | $129K |
| J3490 | Unclassified drugs | <1% | 107,593 | $129K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 537 | $126K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,829 | $123K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 708 | $122K |
| 70498 | <1% | 539 | $122K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,767 | $122K |
| 93970 | <1% | 770 | $112K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,735 | $112K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,628 | $108K |
| 87400 | <1% | 9,663 | $104K | |
| 97165 | <1% | 2,287 | $99K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 526 | $95K |
| 78431 | <1% | 151 | $93K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 35,636 | $93K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,176 | $91K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 31,072 | $90K |
| 87653 | <1% | 2,348 | $88K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,068 | $86K |
| 84702 | <1% | 11,913 | $85K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,056 | $84K |
| 76642 | <1% | 691 | $82K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,253 | $81K |
| 71250 | <1% | 940 | $80K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,599 | $78K |
| 83880 | <1% | 8,747 | $75K | |
| 10060 | <1% | 298 | $70K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,800 | $69K |
| 76536 | <1% | 494 | $68K | |
| 70486 | <1% | 1,075 | $68K | |
| 97602 | <1% | 1,345 | $67K | |
| 73562 | <1% | 2,740 | $64K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,458 | $64K |
| 76801 | <1% | 663 | $64K | |
| 97161 | <1% | 2,930 | $62K | |
| 87480 | <1% | 7,269 | $62K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,376 | $60K |
| 74022 | <1% | 1,696 | $55K | |
| 97802 | <1% | 752 | $51K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,936 | $51K |
| 80081 | <1% | 2,502 | $50K | |
| 73630 | <1% | 2,495 | $50K | |
| 80050 | General health panel | <1% | 4,111 | $49K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,286 | $49K |
| 87660 | <1% | 7,332 | $47K | |
| 72110 | <1% | 1,428 | $47K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,221 | $47K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 487 | $46K |
| 87510 | <1% | 7,264 | $44K | |
| 84439 | <1% | 3,730 | $43K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 128 | $43K |
| 76770 | <1% | 279 | $42K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,223 | $40K |
| 73030 | <1% | 1,865 | $39K | |
| 73610 | <1% | 2,284 | $39K | |
| 73130 | <1% | 1,933 | $39K | |
| 94660 | <1% | 264 | $37K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 99,534 | $37K |
| 80061 | Lipid panel | <1% | 7,019 | $37K |
| 84484 | <1% | 16,453 | $36K | |
| 74018 | <1% | 1,677 | $35K | |
| 81001 | <1% | 26,279 | $33K | |
| 83874 | <1% | 6,420 | $32K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,079 | $31K |
| 93880 | <1% | 391 | $29K | |
| 82553 | <1% | 5,977 | $29K | |
| 73110 | <1% | 1,417 | $28K | |
| 87430 | <1% | 4,117 | $27K | |
| 96376 | <1% | 7,258 | $27K | |
| 86850 | <1% | 2,431 | $27K | |
| 77080 | <1% | 554 | $25K | |
| 0352U | <1% | 811 | $25K | |
| 87077 | <1% | 6,532 | $25K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 17,221 | $25K |
| 97162 | <1% | 846 | $24K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,938 | $24K |
| 0240U | <1% | 187 | $24K | |
| 83690 | <1% | 16,197 | $24K | |
| 12002 | <1% | 94 | $24K | |
| 93922 | <1% | 520 | $23K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,943 | $23K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,768 | $23K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 203 | $23K |
| 99220 | <1% | 150 | $22K | |
| 76376 | <1% | 203 | $21K | |
| 82550 | <1% | 7,696 | $20K | |
| 84144 | <1% | 1,418 | $20K | |
| 93226 | <1% | 366 | $20K | |
| 93925 | <1% | 164 | $19K | |
| 93225 | <1% | 356 | $19K | |
| 87420 | <1% | 2,258 | $18K | |
| 86787 | <1% | 1,530 | $18K | |
| 84112 | <1% | 345 | $18K | |
| 82248 | <1% | 16,663 | $18K | |
| A9270 | Non-covered item or service | <1% | 15,611 | $18K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 53 | $17K |
| 97116 | <1% | 1,177 | $16K | |
| 90002 | <1% | 530 | $16K | |
| 82607 | <1% | 1,562 | $16K | |
| 86140 | <1% | 4,401 | $16K | |
| 73502 | <1% | 1,050 | $16K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,851 | $16K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $16K |
| 85018 | <1% | 3,307 | $16K | |
| 87070 | <1% | 2,535 | $15K | |
| 86803 | <1% | 1,832 | $15K | |
| 83605 | <1% | 8,697 | $15K | |
| 84145 | <1% | 3,732 | $15K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,553 | $15K |
| 85027 | <1% | 4,961 | $15K | |
| 82950 | <1% | 2,613 | $14K | |
| 87186 | <1% | 4,902 | $14K | |
| 70491 | <1% | 44 | $14K | |
| 83735 | <1% | 8,548 | $14K | |
| 87040 | <1% | 3,320 | $13K | |
| 86900 | <1% | 2,437 | $13K | |
| 36600 | <1% | 1,273 | $13K | |
| 87081 | <1% | 3,799 | $13K | |
| 85610 | <1% | 12,066 | $13K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 32 | $13K |
| 85379 | <1% | 6,289 | $12K | |
| 87506 | <1% | 119 | $12K | |
| 85730 | <1% | 8,912 | $12K | |
| 82803 | <1% | 1,935 | $12K | |
| 94726 | <1% | 179 | $12K | |
| 76870 | <1% | 135 | $12K | |
| 94761 | <1% | 3,198 | $12K | |
| 82962 | <1% | 4,567 | $11K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 900 | $11K |
| 74170 | <1% | 73 | $11K | |
| 81003 | <1% | 11,107 | $10K | |
| 82728 | <1% | 1,360 | $10K | |
| 70496 | <1% | 439 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 613 | $10K |
| 82150 | <1% | 3,627 | $10K | |
| 87486 | <1% | 585 | $10K | |
| 73590 | <1% | 847 | $10K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 5,654 | $10K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,298 | $10K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 155 | $10K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 141 | $9K |
| 87581 | <1% | 584 | $9K | |
| 73080 | <1% | 619 | $9K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 577 | $9K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,179 | $9K |
| 94060 | <1% | 195 | $9K | |
| 94729 | <1% | 219 | $8K | |
| 88307 | <1% | 186 | $8K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,662 | $8K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 835 | $8K |
| 82570 | <1% | 2,087 | $8K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,411 | $8K |
| 72131 | <1% | 195 | $7K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 669 | $7K |
| 97014 | <1% | 220 | $7K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,281 | $7K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,767 | $7K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,755 | $7K |
| 85652 | <1% | 3,009 | $7K | |
| 72050 | <1% | 248 | $7K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 150 | $7K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 336 | $6K |
| 99152 | <1% | 1,334 | $6K | |
| 93312 | <1% | 25 | $6K | |
| 78227 | <1% | 16 | $6K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 95 | $6K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,167 | $6K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,645 | $6K |
| 73090 | <1% | 576 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,195 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,973 | $6K |
| 95819 | <1% | 24 | $6K | |
| 72141 | <1% | 32 | $6K | |
| 96367 | <1% | 202 | $6K | |
| 80076 | <1% | 976 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 43 | $6K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 44 | $5K |
| 93325 | <1% | 57 | $5K | |
| 91010 | <1% | 12 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,101 | $5K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,440 | $5K |
| 90021 | <1% | 532 | $5K | |
| 82565 | <1% | 1,549 | $5K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,855 | $5K |
| 83550 | <1% | 996 | $5K | |
| 84146 | <1% | 603 | $5K | |
| 90714 | <1% | 181 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,481 | $4K |
| 80047 | <1% | 2,435 | $4K | |
| 78492 | <1% | 12 | $4K | |
| 84100 | <1% | 2,621 | $4K | |
| A4649 | Surgical supply; miscellaneous | <1% | 28 | $4K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 429 | $4K |
| 90715 | <1% | 165 | $4K | |
| 83540 | <1% | 1,144 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 500 | $4K |
| 94760 | <1% | 1,331 | $4K | |
| 93242 | <1% | 124 | $4K | |
| 86901 | <1% | 3,293 | $4K | |
| 29125 | <1% | 254 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,242 | $3K |
| 82043 | <1% | 1,368 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,682 | $3K |
| S9484 | Crisis intervention mental health services, per hour | <1% | 62 | $3K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,840 | $3K |
| 86592 | <1% | 345 | $3K | |
| 86038 | <1% | 382 | $3K | |
| 94799 | <1% | 717 | $3K | |
| 87075 | <1% | 1,217 | $3K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,349 | $3K |
| 73700 | <1% | 40 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 69 | $3K |
| 87205 | <1% | 1,719 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 272 | $3K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 114 | $2K |
| 73552 | <1% | 369 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,300 | $2K |
| 82746 | <1% | 421 | $2K | |
| 84481 | <1% | 318 | $2K | |
| 83655 | <1% | 164 | $2K | |
| 84153 | <1% | 284 | $2K | |
| 84436 | <1% | 1,053 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 736 | $2K |
| 97166 | <1% | 90 | $2K | |
| 73140 | <1% | 221 | $2K | |
| 51701 | <1% | 816 | $2K | |
| 99205 | Prolong outpt/office vis | <1% | 480 | $2K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 27 | $2K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 31 | $2K |
| 72100 | <1% | 116 | $2K | |
| 87149 | <1% | 21 | $2K | |
| 90686 | <1% | 232 | $2K | |
| 92523 | <1% | 28 | $2K | |
| 82784 | <1% | 213 | $2K | |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | <1% | 50 | $2K |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 16 | $2K |
| 82247 | <1% | 302 | $2K | |
| 71101 | <1% | 146 | $2K | |
| 86780 | <1% | 171 | $2K | |
| 84403 | <1% | 151 | $2K | |
| 88341 | <1% | 26 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,684 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 746 | $1K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,073 | $1K |
| H0001 | Alcohol and/or drug assessment | <1% | 25 | $1K |
| 80069 | <1% | 788 | $1K | |
| 72072 | <1% | 97 | $1K | |
| 99423 | <1% | 13 | $1K | |
| 82951 | <1% | 95 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,513 | $1K |
| 84156 | <1% | 580 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 249 | $1K |
| 36410 | <1% | 184 | $970.18 | |
| 82533 | <1% | 91 | $967.14 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,456 | $944.50 |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 37 | $926.79 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 26 | $912.37 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 55 | $849.49 |
| 83001 | <1% | 72 | $842.41 | |
| 73560 | <1% | 142 | $828.49 | |
| 97035 | <1% | 98 | $816.49 | |
| 87536 | <1% | 28 | $787.24 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 672 | $778.76 |
| 97032 | <1% | 35 | $755.82 | |
| 87340 | <1% | 91 | $709.77 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,000 | $662.08 |
| 85014 | <1% | 522 | $625.27 | |
| 80164 | <1% | 144 | $624.53 | |
| 51702 | <1% | 39 | $583.34 | |
| 86376 | <1% | 62 | $560.25 | |
| 51798 | <1% | 514 | $539.90 | |
| 82952 | <1% | 97 | $514.95 | |
| 92610 | <1% | 13 | $471.35 | |
| 36430 | <1% | 28 | $437.56 | |
| 86308 | <1% | 197 | $436.96 | |
| 74019 | <1% | 13 | $429.64 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $392.47 |
| 83525 | <1% | 26 | $388.24 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 108 | $377.72 |
| 73100 | <1% | 101 | $353.55 | |
| 84402 | <1% | 28 | $352.10 | |
| 72128 | <1% | 25 | $313.93 | |
| 29505 | <1% | 16 | $275.50 | |
| 82272 | <1% | 403 | $269.11 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,126 | $266.51 |
| 86800 | <1% | 31 | $253.87 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 384 | $247.85 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,077 | $247.61 |
| 84132 | <1% | 472 | $246.47 | |
| 84550 | <1% | 79 | $237.31 | |
| 86923 | <1% | 44 | $205.64 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 190 | $203.00 |
| 83516 | <1% | 27 | $202.65 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 802 | $195.19 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 428 | $190.08 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 409 | $188.20 |
| 82670 | <1% | 13 | $187.42 | |
| 73000 | <1% | 29 | $180.89 | |
| 84270 | <1% | 13 | $167.57 | |
| 72170 | <1% | 84 | $161.30 | |
| 73060 | <1% | 49 | $145.68 | |
| 84425 | <1% | 33 | $135.67 | |
| 88342 | <1% | 121 | $134.74 | |
| 0296T | <1% | 13 | $133.23 | |
| 81025 | <1% | 3,304 | $131.39 | |
| 85046 | <1% | 110 | $123.51 | |
| 85049 | <1% | 227 | $112.11 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 412 | $109.06 |
| 83615 | <1% | 202 | $107.39 | |
| 83002 | <1% | 14 | $100.60 | |
| 86431 | <1% | 20 | $94.86 | |
| 83921 | <1% | 14 | $92.85 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 730 | $91.47 |
| 83520 | <1% | 14 | $90.09 | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 70 | $83.59 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 349 | $82.90 |
| 87147 | <1% | 55 | $79.92 | |
| 82947 | <1% | 39 | $72.70 | |
| 85007 | <1% | 17 | $71.60 | |
| 88304 | <1% | 140 | $63.32 | |
| 82140 | <1% | 43 | $58.28 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 28 | $51.33 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14 | $50.00 |
| G0168 | Wound closure utilizing tissue adhesive(s) only | <1% | 33 | $47.50 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 368 | $46.28 |
| 80320 | <1% | 405 | $43.71 | |
| G0008 | Administration of influenza virus vaccine | <1% | 87 | $37.51 |
| 87102 | <1% | 39 | $34.01 | |
| 80074 | <1% | 13 | $33.06 | |
| S4991 | Nicotine patches, non-legend | <1% | 294 | $31.02 |
| 87116 | <1% | 68 | $30.67 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 353 | $20.98 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,338 | $18.58 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 792 | $18.49 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 910 | $17.54 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 197 | $12.36 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 188 | $8.74 |
| 87206 | <1% | 53 | $5.74 | |
| 99417 | Prolong home eval add 15m | 0% | 295 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 156 | $0.00 |
| C1769 | Guide wire | 0% | 183 | $0.00 |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 0% | 114 | $0.00 |
| J7605 | Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms | 0% | 115 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 30 | $0.00 |
| 93320 | 0% | 12 | $0.00 | |
| 82330 | 0% | 50 | $0.00 | |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | 0% | 25 | $0.00 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 18 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | 0% | 46 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 26 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 163 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 431 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 270 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 174 | $0.00 |
| 89051 | 0% | 38 | $0.00 | |
| 29105 | 0% | 44 | $0.00 | |
| 80143 | 0% | 52 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 387 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 558 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 185 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 29 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 14 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 68 | $0.00 |
| 29515 | 0% | 31 | $0.00 | |
| 80179 | 0% | 48 | $0.00 | |
| 31720 | 0% | 41 | $0.00 | |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 0% | 26 | $0.00 |
| C1729 | Catheter, drainage | 0% | 34 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 39 | $0.00 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 0% | 40 | $0.00 |
| 82310 | 0% | 15 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 39 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 16 | $0.00 |
| 87207 | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOODRICH, JOHN (INTERIM PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Bryan Medical Center | Lincoln, NE | $161K |
| Bryan Medical Center | Lincoln, NE | $15K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.